Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 16,128 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Contact Dermatitis, Eczema, Contact
Interventions: Epikeia Coatings; Device
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Skin Reaction to Mechanical, Thermal and Radiation Stimuli, Skin Sensitisation
Interventions: Sponsor incisional negative pressure wound therapy device and dressing, Standard of Care incisional negative pressure wound therapy system; Device
Lead sponsor: DeRoyal Industries, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Acne Vulgaris
Interventions: Trifarotene; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 9 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 9
States / cities: Fort Smith, Arkansas • Beverly, Massachusetts • Portsmouth, New Hampshire + 6 more

Conditions: Rosacea
Interventions: CLS001 (Omiganan), Vehicle; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Manhattan Beach, California + 17 more

Conditions: Metastatic Breast Cancer
Interventions: Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 22 more

Conditions: Breast Neoplasms
Interventions: MEDI4736; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
Interventions: Team-Based Connected Health (TCH); Other
Lead sponsor: University of Southern California; Other
Eligibility: 1 Year and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Staphylococcus Aureus, HIV Infections
Interventions: rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography, Surgical Procedure, VLP-encapsulated TLR9 Agonist CMP-001; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 187
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 134 more

Conditions: Financial Toxicity, Cancer, Question Prompt List, Breast Cancer, Prostate Cancer
Interventions: Group 2: The DISCO App, Group 1: Usual Care, Group 3: The DISCO App + Booster; Behavioral
Lead sponsor: Lauren Hamel; Other
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Skin Infection
Interventions: Medicinal honey, Bacitracin; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Breast Neoplasms
Interventions: Vitamin D, Calcium carbonate, Vitamin D, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Active Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 62
States / cities: Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 48
States / cities: Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more

Conditions: Anal Cancer, Precancerous Condition
Interventions: cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination; Drug · Genetic · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Online Self-Management; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Scleroderma
Interventions: UVA-1 Phototherapy, UV-Blocking Glove; Device · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Murray, Utah

Conditions: B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
Interventions: Nivolumab, Epacadostat, Chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Breast Cancer
Interventions: Green tea extract supplement, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 1,075 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 5
States / cities: Edina, Minnesota • Maple Grove, Minnesota • Minneapolis, Minnesota + 2 more

Conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: Fulvestrant, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 32 Years to 91 Years · Female only
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 51
States / cities: Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more

Conditions: Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Interventions: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more

Conditions: Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 2
States / cities: Bethesda, Maryland • Rockville, Maryland

Conditions: Wounds, Diabetes Complications, Diabetic Foot, Foot Ulcer
Interventions: Online Wound Electronic Medical Record; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Tuscon, Arizona • Pomona, California + 8 more

Conditions: Breast Neoplasms
Interventions: accelerated partial breast irradiation; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Novel Topical Treatment of Hand Dermatitis (Eczema)

Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer

The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown

High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

RAHelp.Org: An Online Self Management Program for Adults With Rheumatoid Arthritis

UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Green Tea and Reduction of Breast Cancer Risk

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Cancer in Inherited Bone Marrow Failure Syndromes

Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics

Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer